AAAAAA
Results:
1-18
|
Results: 18
Authors:
Kelland, LR
Smith, V
Valenti, M
Patterson, L
Clarke, PA
Detre, S
End, D
Howes, AJ
Dowsett, M
Workman, P
Johnston, SRD
Citation: Lr. Kelland et al., Preclinical antitumor activity and pharmacodynamic studies with the farnesylprotein transferase inhibitor R115777 in human breast cancer, CLIN CANC R, 7(11), 2001, pp. 3544-3550
Authors:
Seddon, BM
Honess, DJ
Vojnovic, B
Tozer, GM
Workman, P
Citation: Bm. Seddon et al., Measurement of tumor oxygenation: In vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the P22 tumor, RADIAT RES, 155(6), 2001, pp. 837-846
Authors:
Smith, V
Raynaud, F
Workman, P
Kelland, LR
Citation: V. Smith et al., Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol, MOLEC PHARM, 60(5), 2001, pp. 885-893
Authors:
Hostein, I
Robertson, D
DiStefano, F
Workman, P
Clarke, PA
Citation: I. Hostein et al., Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis, CANCER RES, 61(10), 2001, pp. 4003-4009
Authors:
Anderson, H
Price, P
Blomley, M
Leach, MO
Workman, P
Citation: H. Anderson et al., Measuring changes in human tumour vasculature in response to therapy usingfunctional imaging techniques, BR J CANC, 85(8), 2001, pp. 1085-1093
Authors:
Bailey, SM
Lewis, AD
Patterson, LH
Fisher, GR
Knox, RJ
Workman, P
Citation: Sm. Bailey et al., Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species, BIOCH PHARM, 62(4), 2001, pp. 461-468
Authors:
Clarke, PA
Poele, RT
Wooster, R
Workman, P
Citation: Pa. Clarke et al., Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential, BIOCH PHARM, 62(10), 2001, pp. 1311-1336
Authors:
Turlais, F
Hardcastle, A
Rowlands, M
Newbatt, Y
Bannister, A
Kouzarides, T
Workman, P
Aherne, GW
Citation: F. Turlais et al., High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate), ANALYT BIOC, 298(1), 2001, pp. 62-68
Authors:
Workman, P
Citation: P. Workman, Signal transduction pathways - A goldmine for therapeutic targets, CANC DRUG, 8, 2001, pp. 1-20
Authors:
Clarke, PA
Hostein, I
Banerji, U
Di Stefano, F
Maloney, A
Walton, M
Judson, I
Workman, P
Citation: Pa. Clarke et al., Gene expression profiling of human colon cancer cells following inhibitionof signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone, ONCOGENE, 19(36), 2000, pp. 4125-4133
Authors:
Sharp, SY
Kelland, LR
Valenti, MR
Brunton, LA
Hobbs, S
Workman, P
Citation: Sy. Sharp et al., Establishment of an isogenic human colon tumor model for NQO1 gene expression: Application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo, MOLEC PHARM, 58(5), 2000, pp. 1146-1155
Authors:
Workman, P
Citation: P. Workman, Emerging molecular therapies - Small-molecule drugs, PRINCIPLES OF MOLECULAR ONCOLOGY, 2000, pp. 421-437
Authors:
Kelland, LR
Sharp, SY
Rogers, PM
Myers, TG
Workman, P
Citation: Lr. Kelland et al., DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90, J NAT CANC, 91(22), 1999, pp. 1940-1949
Authors:
Gelmon, KA
Eisenhauer, EA
Harris, AL
Ratain, MJ
Workman, P
Citation: Ka. Gelmon et al., Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?, J NAT CANC, 91(15), 1999, pp. 1281-1287
Authors:
Garrett, MD
Workman, P
Citation: Md. Garrett et P. Workman, Discovering novel chemotherapeutic drugs for the third millennium, EUR J CANC, 35(14), 1999, pp. 2010-2030
Authors:
Aboagye, EO
Kelson, AB
Tracy, M
Workman, P
Citation: Eo. Aboagye et al., Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography (vol 13, pg 703, 1998), ANTI-CAN DR, 13(8), 1998, pp. 1009-1010
Authors:
Stratford, IJ
Workman, P
Citation: Ij. Stratford et P. Workman, Bioreductive drugs into the next millennium, ANTI-CAN DR, 13(6), 1998, pp. 519-528
Authors:
Aboagye, EO
Kelson, AB
Tracy, M
Workman, P
Citation: Eo. Aboagye et al., Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography, ANTI-CAN DR, 13(6), 1998, pp. 703-730
Risultati:
1-18
|